CN Stock MarketDetailed Quotes

Zhejiang Huakang Pharmaceutical (605077)

Watchlist
  • 15.42
  • -0.15-0.96%
Trading Jan 16 13:21 CST
4.67BMarket Cap18.69P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Zhejiang Huakang Pharmaceutical (605077) Revenue Breakdown Overview

By Product

Currency:CNY
2025/H1
Stock NameRevenueRatio
晶体糖醇产品1.01B54.36%
液体糖、醇及其他产品605.48M32.45%
Other245.89M13.18%
Total special adjustments273.99K0.01%

By Industry

Currency:CNY
2024/FY
Stock NameRevenueRatio
Food manufacture2.79B99.51%
Other business13.79M0.49%

By Country/Region

Currency:CNY
2025/H1
Stock NameRevenueRatio
Territory1.15B61.71%
Overseas714.19M38.28%
Total special adjustments273.99K0.01%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
HK Tech and Internet Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +16.81%
Sample Name
Sample Code
 +15.49%
Sample Name
Sample Code
 +13.58%
4
BIDU-SW
09888
+6.04%
5
KUAISHOU-W
01024
+4.15%
View More
Nancy Pelosi Portfolio
No. Symbol % Chg
Sample Name
Sample Code
 +6.63%
Sample Name
Sample Code
 +3.27%
Sample Name
Sample Code
 +2.15%
4
NVIDIA
NVDA
+2.13%
5
Broadcom
AVGO
+0.92%
Will the 'tariff stick' strike again? Will the market remain 'reactive'?
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -